全文获取类型
收费全文 | 2499篇 |
免费 | 190篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 124篇 |
妇产科学 | 31篇 |
基础医学 | 321篇 |
口腔科学 | 28篇 |
临床医学 | 233篇 |
内科学 | 669篇 |
皮肤病学 | 65篇 |
神经病学 | 196篇 |
特种医学 | 149篇 |
外科学 | 289篇 |
综合类 | 23篇 |
预防医学 | 157篇 |
眼科学 | 58篇 |
药学 | 216篇 |
中国医学 | 13篇 |
肿瘤学 | 107篇 |
出版年
2023年 | 11篇 |
2022年 | 20篇 |
2021年 | 64篇 |
2020年 | 26篇 |
2019年 | 57篇 |
2018年 | 74篇 |
2017年 | 65篇 |
2016年 | 52篇 |
2015年 | 58篇 |
2014年 | 80篇 |
2013年 | 105篇 |
2012年 | 125篇 |
2011年 | 143篇 |
2010年 | 116篇 |
2009年 | 94篇 |
2008年 | 117篇 |
2007年 | 104篇 |
2006年 | 120篇 |
2005年 | 109篇 |
2004年 | 86篇 |
2003年 | 81篇 |
2002年 | 85篇 |
2001年 | 66篇 |
2000年 | 79篇 |
1999年 | 56篇 |
1998年 | 38篇 |
1997年 | 45篇 |
1996年 | 50篇 |
1995年 | 43篇 |
1994年 | 32篇 |
1993年 | 44篇 |
1992年 | 46篇 |
1991年 | 32篇 |
1990年 | 41篇 |
1989年 | 30篇 |
1988年 | 36篇 |
1987年 | 21篇 |
1986年 | 24篇 |
1985年 | 20篇 |
1984年 | 13篇 |
1981年 | 16篇 |
1977年 | 12篇 |
1976年 | 23篇 |
1974年 | 13篇 |
1973年 | 11篇 |
1972年 | 10篇 |
1971年 | 9篇 |
1970年 | 10篇 |
1969年 | 10篇 |
1966年 | 9篇 |
排序方式: 共有2695条查询结果,搜索用时 15 毫秒
81.
Platelet alpha-granule and plasma membrane share two new components: CD9 and PECAM-1 总被引:1,自引:2,他引:1
CD9 (p24) and PECAM1 (CD31) antigens are well-defined components of the platelet plasma membrane. Both are integral glycoproteins (GPs) implicated in the adhesive and aggregative properties of human platelets. In the present report, we have investigated their subcellular localization using immunoelectron microscopy. The monospecificity of the two polyclonal antibodies used was confirmed by immunoblotting. On normal resting platelets, immunolabeling for CD9 and PECAM1 was found lining the plasma membrane and the luminal face of the open canalicular system. Some labeling was also consistently found on the alpha-granule limiting membrane. This was confirmed by double labeling experiments in which fibrinogen and von Willebrand factor (vWF) were used as alpha-granule markers. CD9 and PECAM-1 were found lining the membrane of the same granules that contained fibrinogen and vWF in their matrix. CD9 and PECAM-1 thus appear to have an intracellular distribution identical to GPIIb-IIIa, a major aggregation platelet receptor. To rule out a cross-reactivity of the two polyclonal antibodies with GPIIb/IIIa, we studied PECAM1 and CD9 expression on the platelets from a patient with type I Glanzmann's thrombasthenia whose platelets are devoid of GPIIb/IIIa. The same pattern of labeling was observed for both antigens as for normal platelets. Normal platelets were further observed after stimulation by agonists that either fail to induce (ADP) or induce granule secretion (thrombin). After treatment with ADP, platelets changed shape and centralized their granules; the plasma membrane immunolabeling remained unchanged; and gold particles were still found decorating the periphery of the centralized alpha- granules. After thrombin treatment, alpha-granules fused with the platelet membrane and secretion occurred. A significant increase of labeling was then observed on the platelet surface. From these results we conclude that the alpha-granule membrane contains two additional receptors in common with the plasma membrane. This suggests that alpha- granule membrane receptors may originate from a dual mechanism: direct targeting from the Golgi complex in megakaryocytes (for alpha-granule- specific receptors such as P-selectin) or by endocytosis from the plasma membrane (for proteins distributed in the two compartments). 相似文献
82.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model
下载免费PDF全文
![点击此处可从《Oral diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
83.
BACKGROUND:
Selecting candidates for plastic surgery residency training remains a challenge. In the United States, academic measures (United States Medical Licensing Exam Step I scores, medical school class rank and publications) are used as primary criteria for candidate selection for residency. In contrast, Canadian medical education de-emphasizes academic measures by using a pass-fail grading system. As a result, choosing residents from many qualified applicants may pose a challenge for Canadian programs without objective measures of academic success.METHODS:
A 25-question online survey was distributed to program directors of Canadian plastic surgery residency-training programs. Program directors commented on number of yearly residents and applicants; application sections (ranked in importance using a Likert scale); interview invitation and rank-order list determination; and their satisfaction with the selection process.RESULTS:
Ten Canadian plastic surgery program directors responded (90.9% response rate). The most important application components determining invitation to interview were letters of reference from a plastic surgeon (mean importance of 5.0 on the Likert scale), clinical electives in plastic surgery (mean 4.6) and electives with their program (mean 4.5). Applicants invited for interview were assessed on the quality of their responses to questions, maturity and personality. The majority of program directors agreed that a clinical elective with their program was important for consideration on their rank-order list. Program directors were neutral on their satisfaction with the selection process.CONCLUSION:
Canadian plastic surgery residency programs emphasize clinical electives with their program and letters of reference from colleagues when selecting applicants for interviews. In contrast to their American counterparts, Canadian program directors rely on clinical interactions with prospective residents in the absence of objective academic measures. 相似文献84.
85.
86.
87.
Laura Villarreal‐Martínez Jaime García‐Chvez Berenice Snchez‐Jara Aida Mashenka Moreno‐Gonzlez Janet Soto‐Padilla Efraín Aquino‐Fernndez Rogelio Paredes‐Aguilera Karla Maldonado‐Silva Cecilia Rodríguez‐Castillejos Ana Itamar Gonzlez‐vila María Mora‐Torres Hector Manuel Tiznado‐García Natalia Elizabeth Padilla‐Durn Nuria Citlali Luna‐Silva Eric Israel Gutirrez‐Jurez Jorge Nemi‐Cueto Claudia Sofia Gmez‐Gonzlez Ricardo De Len‐Figueroa Adela Lpez‐Miranda Mirna Guadalupe Ríos‐Osuna Edna Liliana Tamez‐Gmez Elio Aarn Reyes‐Espinoza Irving Armando Domínguez‐Varela Gerardo Gonzlez‐Martínez Elias Adn Godoy‐Salinas 《Haemophilia》2020,26(2):290-297
88.
89.
Kevin M. Pantalone DO Kashif Munir MD Clinton M. Hasenour PhD Charles M. Atisso PhD Oralee J. Varnado PhD Juan M. Maldonado PharmD Manige Konig MD 《Diabetes, obesity & metabolism》2020,22(12):2209-2226
Despite treatment advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease (CVD) remains the leading cause of morbidity and mortality in people with diabetes. People with type 2 diabetes (T2D) have a 2- to 4-fold increased risk of CVD and CV death. Individuals with T2D have not seen the same improvements in CV morbidity and mortality as those without T2D. Given this, it is important to understand the CV impact of drugs used to treat T2D. In patients with T2D, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in HbA1c and body weight regardless of their differences in chemical structure and pharmacokinetic variables. Glycaemic efficacy, accompanied by the potential for weight reduction and a low risk of hypoglycaemia, has moved GLP-1 RAs to the first treatment of choice following metformin monotherapy in the latest American Diabetes Association treatment guidelines. Additionally, all GLP-1 RAs have shown CV safety and several have proven CV benefit. GLP-1 RAs have been evaluated in cardiovascular outcomes trials (CVOTs) of varying sizes, designs and patient populations with differing reported effects on CV outcomes. The purpose of this article is to review the completed GLP-1 RA CVOTs with special attention to how their design, size, patient populations and conduct may influence the interpretation of results. 相似文献
90.